| Literature DB >> 11686860 |
Abstract
Despite much information on their catalytic properties and gene regulation, we actually know very little of what matrix metalloproteinases (MMPs) do in tissues. The catalytic activity of these enzymes has been implicated to function in normal lung biology by participating in branching morphogenesis, homeostasis, and repair, among other events. Overexpression of MMPs, however, has also been blamed for much of the tissue destruction associated with lung inflammation and disease. Beyond their role in the turnover and degradation of extracellular matrix proteins, MMPs also process, activate, and deactivate a variety of soluble factors, and seldom is it readily apparent by presence alone if a specific proteinase in an inflammatory setting is contributing to a reparative or disease process. An important goal of MMP research will be to identify the actual substrates upon which specific enzymes act. This information, in turn, will lead to a clearer understanding of how these extracellular proteinases function in lung development, repair, and disease.Entities:
Mesh:
Substances:
Year: 2000 PMID: 11686860 PMCID: PMC59564 DOI: 10.1186/rr33
Source DB: PubMed Journal: Respir Res ISSN: 1465-9921
Matrix metalloproteinases (MMPs)
| MMP designation* | Common name (other or previous names) |
| MMP-1 | Collagenase-1 (fibroblast collagenase, interstitial |
| collagenase) | |
| MMP-2 | Gelatinase-A (72 kDa gelatinase, 72 kDa type IV |
| collagenase) | |
| MMP-3 | Stromelysin-1 (transin-1) |
| MMP-7 | Matrilysin (PUMP) |
| MMP-8 | Collagenase-2 (neutrophil collagenase) |
| MMP-9 | Gelatinase-B (92 kDa gelatinase, 92 kDa type IV |
| collagenase) | |
| MMP-10 | Stromelysin-2 (transin-2) |
| MMP-11 | Stromelysin-3 |
| MMP-12 | Macrophage metalloelastase |
| MMP-13 | Collagenase-3 (rat collagenase) |
| MMP-14 | MT1-MMP (membrane-type MMP) |
| MMP-15 | MT2-MMP |
| MMP-16 | MT3-MMP |
| MMP-17 | MT4-MMP |
| MMP-18 | Collagenase-4† |
| MMP-19 | |
| MMP-20 | Enamelysin |
| MMP-21 | |
| MMP-22 | |
| MMP-23 | CA-MMP |
| MMP-24 | MT5-MMP |
| MMP-25 | Leukolysin (MT6-MMP) |
| MMP-26 | Endometase (matrilysin-2) |
*There is no MMP-4, MMP-5, or MMP-6. After matrilysin was discovered and designated as MMP-7, MMP-4 to MMP-6 were determined to be either MMP-2 or MMP-3. †Collagenase-4 was isolated from Xenopus. A mammalian homolog has not been found.
Phenotype of matrix metalloproteinase (MMP) knockout mice
| Phenotype | |||
| Gene | Lethal | Unchallenged | Challenged* |
| Gelatinase-A (MMP-2) | No | • None [ | • Reduction in angiogenesis and tumor growth [ |
| Stromelysin-1 (MMP-3) | No | • None [ | • Impaired wound contraction [ |
| • Reduced contact hypersensitivity response [ | |||
| • Accelerated arthritis [ | |||
| Matrilysin (MMP-7) | No | • Lack of activated antimicrobial peptides [ | ✓ Inability to repair mucosal epithelial wounds [ |
| • Reduced ability to kill pathogenic bacteria [ | |||
| • Reduced tumorigenesis [ | |||
| Gelatinase-B (MMP-9) | No | • Transient slowing of long bone growth | ✓ Normal neutrophil extravasation [ |
| secondary to reduced angiogenesis [ | ✓ Lack of alveolar brochiolization in fibrosis [ | ||
| • Resistant to induced blister formation [ | |||
| • Persistent contact hypersensitivity response [ | |||
| • Protection against aortic aneurysm formation [ | |||
| • Reduced ventricular enlargement and rupture | |||
| postmyocardial infarction [ | |||
| • Delayed tumor progression and reduced metastases [ | |||
| Stromelysin-3 (MMP-11) | No | • None [ | • Less chemically induced tumors and reduced tumor |
| cell implantation [ | |||
| • Accelerated and enhanced neointimal formation [ | |||
| Macrophage | No | • None [ | ✓ Reduced elastolytic capacity of macrophages [ |
| metalloelastase (MMP-12) | ✓ Protection against smoking-induced | ||
| emphysema [ | |||
| • Reduced ability of macrophages to migrate through | |||
| matrix [ | |||
| MT1-MMP (MMP-14) | Yes | • Severe skeletal abnormalities [ | • Not yet assessed |
*✓, Assessed in lung.
Figure 1Ex vivo infection of human tracheal explants and infection of human tracheal epithelial cells. (a) Pieces (1 cm3) of freshly isolated normal adult human trachea were infected with the Escherichia coli isolates NU14 (fimH+) and NU14-1 (fimH-) for 90 min and incubated for 24 h in fresh media containing 50 μg/ml gentamicin as previously described [40]. NU14 is an E. coli strain isolated from a patient with cystitis and expresses FimH-containing type 1 pili. NU14-1 is a fimH- mutant in which a chloramphenicol cassette was recombined into the fimH gene in the chromosome of NU14 [25]. FimH is a mannose-binding adhesin that mediates the interaction of type 1-piliated bacteria with mannose-containing glycoproteins on eukaryotic cell surfaces. Released and activated matrilysin was detected by western analysis. (b) Human tracheal primary epithelial cells were infected with the type 1 piliated recombinant strains ORN103/pSH2 (fimH+) and ORN103/pUT2002 (fimH-) for 90 min, and allowed to condition fresh media for 48 h. Matrilysin secretion was assessed by immunoblotting. (Reproduced from [40]; copyright permission of The Rockefeller University Press.)
Figure 2Expression of matrilysin in injured tracheal explants. Sections of a segment of normal human trachea were incubated in culture medium at 37°C for 5 days (d5) before fixation and immunohistochemistry for matrilysin protein [39]. The edge of the biopsy and the margin of basement membrane, which is the clear area underlying the epithelium, is marked by the large arrow. By 5 days postplating, the epithelial cells have migrated progressively and intense staining for matrilysin is observed in these migrating cells, especially those in close contact with the underlying matrix. Release of matrilysin towards the matrix was seen in association with some cells (small arrows). No signal was seen in sections processed with preimmune serum (PI). Bar = 20 μm. (Reproduced from [39]; copyright permission of The American Society for Clinical Investigation.)